Search Results - Leip, Eric

  • Showing 1 - 13 results of 13
Refine Results
  1. 1
    Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer

    Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic... by Moy, Beverly, Neven, Patrick, Lebrun, Fabienne, Bellet, Meritxell, Xu, Binghe, Sarosiek, Tomasz, Chow, Louis, Goss, Paul, Zacharchuk, Charles, Leip, Eric, Turnbull, Kathleen, Bardy-Bouxin, Nathalie, Duvillié, Ladan, Láng, István

    Published 2014
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  2. 2
    Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer

    Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-P... by Moy, Beverly, Neven, Patrick, Lebrun, Fabienne, Bellet, Meritxell, Xu, Binghe, Sarosiek, Tomasz, Chow, Louis, Goss, Paul, Zacharchuk, Charles, Leip, Eric, Turnbull, Kathleen, Bardy-Bouxin, Nathalie, Duvillié, Ladan, Láng, István

    Published 2014
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  3. 3
    Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib

    Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib by Cortes, Jorge E., Khoury, Hanna J., Kantarjian, Hagop M., Lipton, Jeff H., Kim, Dong‐Wook, Schafhausen, Philippe, Matczak, Ewa, Leip, Eric, Noonan, Kay, Brümmendorf, Tim H., Gambacorti‐Passerini, Carlo

    Published 2016
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  4. 4
    Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

    Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure by Khoury, H. Jean, Cortes, Jorge E., Kantarjian, Hagop M., Gambacorti-Passerini, Carlo, Baccarani, Michele, Kim, Dong-Wook, Zaritskey, Andrey, Countouriotis, Athena, Besson, Nadine, Leip, Eric, Kelly, Virginia, Brümmendorf, Tim H.

    Published 2012
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  5. 5
    Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

    Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors by Kantarjian, Hagop M., Cortes, Jorge E., Kim, Dong-Wook, Khoury, H. Jean, Brümmendorf, Tim H., Porkka, Kimmo, Martinelli, Giovanni, Durrant, Simon, Leip, Eric, Kelly, Virginia, Turnbull, Kathleen, Besson, Nadine, Gambacorti-Passerini, Carlo

    Published 2014
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  6. 6
    Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

    Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors by Gambacorti‐Passerini, Carlo, Kantarjian, Hagop M., Kim, Dong‐Wook, Khoury, Hanna J., Turkina, Anna G., Brümmendorf, Tim H., Matczak, Ewa, Bardy‐Bouxin, Nathalie, Shapiro, Mark, Turnbull, Kathleen, Leip, Eric, Cortes, Jorge E.

    Published 2015
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  7. 7
    Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study

    Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study by Gambacorti-Passerini, Carlo, Cortes, Jorge E., Lipton, Jeff H., Kantarjian, Hagop M., Kim, Dong-Wook, Schafhausen, Philippe, Crescenzo, Rocco, Bardy-Bouxin, Nathalie, Shapiro, Mark, Noonan, Kay, Leip, Eric, DeAnnuntis, Liza, Brümmendorf, Tim H., Khoury, H. Jean

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  8. 8
    Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

    Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib by Cortes, Jorge E., Kantarjian, Hagop M., Brümmendorf, Tim H., Kim, Dong-Wook, Turkina, Anna G., Shen, Zhi-Xiang, Pasquini, Ricardo, Khoury, H. Jean, Arkin, Steven, Volkert, Angela, Besson, Nadine, Abbas, Richat, Wang, Junyuan, Leip, Eric, Gambacorti-Passerini, Carlo

    Published 2011
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  9. 9
    Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib

    Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib by Cortes, Jorge E., Khoury, H. Jean, Kantarjian, Hagop, Brümmendorf, Tim H., Mauro, Michael J., Matczak, Ewa, Pavlov, Dmitri, Aguiar, Jean M., Fly, Kolette D., Dimitrov, Svetoslav, Leip, Eric, Shapiro, Mark, Lipton, Jeff H., Durand, Jean-Bernard, Gambacorti-Passerini, Carlo

    Published 2016
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  10. 10
    Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

    Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial by Cortes, Jorge E., Gambacorti-Passerini, Carlo, Deininger, Michael W., Mauro, Michael J., Chuah, Charles, Kim, Dong-Wook, Dyagil, Irina, Glushko, Nataliia, Milojkovic, Dragana, le Coutre, Philipp, Garcia-Gutierrez, Valentin, Reilly, Laurence, Jeynes-Ellis, Allison, Leip, Eric, Bardy-Bouxin, Nathalie, Hochhaus, Andreas, Brümmendorf, Tim H.

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  11. 11
    Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

    Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study by Hochhaus, Andreas, Gambacorti-Passerini, Carlo, Abboud, Camille, Gjertsen, Bjørn Tore, Brümmendorf, Tim H., Smith, B. Douglas, Ernst, Thomas, Giraldo-Castellano, Pilar, Olsson-Strömberg, Ulla, Saussele, Susanne, Bardy-Bouxin, Nathalie, Viqueira, Andrea, Leip, Eric, Russell-Smith, T. Alexander, Leone, Jocelyn, Rosti, Gianantonio, Watts, Justin, Giles, Francis J.

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  12. 12
    Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

    Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial by Brümmendorf, Tim H., Cortes, Jorge E., Milojkovic, Dragana, Gambacorti-Passerini, Carlo, Clark, Richard E., le Coutre, Philipp, Garcia-Gutierrez, Valentin, Chuah, Charles, Kota, Vamsi, Lipton, Jeffrey H., Rousselot, Philippe, Mauro, Michael J., Hochhaus, Andreas, Hurtado Monroy, Rafael, Leip, Eric, Purcell, Simon, Yver, Anne, Viqueira, Andrea, Deininger, Michael W.

    Published 2022
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  13. 13
    Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

    Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up by Gambacorti-Passerini, Carlo, Brümmendorf, Tim H, Kim, Dong-Wook, Turkina, Anna G, Masszi, Tamas, Assouline, Sarit, Durrant, Simon, Kantarjian, Hagop M, Khoury, H Jean, Zaritskey, Andrey, Shen, Zhi-Xiang, Jin, Jie, Vellenga, Edo, Pasquini, Ricardo, Mathews, Vikram, Cervantes, Francisco, Besson, Nadine, Turnbull, Kathleen, Leip, Eric, Kelly, Virginia, Cortes, Jorge E

    Published 2014
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:

Search Tools: